Truist Financial Boosts Quest Diagnostics (NYSE:DGX) Price Target to $260.00

Quest Diagnostics (NYSE:DGX) had its price target upped by research analysts at Truist Financial from $250.00 to $260.00 in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a “hold” rating on the medical research company’s stock. Truist Financial’s target price suggests a potential upside of 10.61% from the company’s current price.

Several other brokerages have also recently issued reports on DGX. Robert W. Baird raised their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. UBS Group upped their price target on shares of Quest Diagnostics from $232.00 to $245.00 and gave the company a “neutral” rating in a report on Tuesday, September 8th. Barclays increased their price target on shares of Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, August 12th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Quest Diagnostics presently has an average rating of “Moderate Buy” and a consensus target price of $237.08.

Quest Diagnostics Trading Down 4.0%

NYSE DGX opened at $235.06 on Monday. The firm has a market cap of $25.94 billion, a PE ratio of 24.95, a price-to-earnings-growth ratio of 2.24 and a beta of 0.55. Quest Diagnostics has a 1-year low of $171.18 and a 1-year high of $248.84. The stock has a 50-day moving average of $234.59 and a 200-day moving average of $211.09. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, sell-side analysts forecast that Quest Diagnostics will post 11.15 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Michael E. Prevoznik sold 22,677 shares of Quest Diagnostics stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the sale, the senior vice president owned 37,557 shares of the company’s stock, valued at approximately $9,130,482.27. The trade was a 37.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the transaction, the chief executive officer owned 122,423 shares in the company, valued at $29,714,510.56. This represents a 7.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 34,277 shares of company stock worth $8,316,493. 0.88% of the stock is currently owned by corporate insiders.

Institutional Trading of Quest Diagnostics

Large investors have recently bought and sold shares of the company. Concurrent Investment Advisors LLC increased its position in shares of Quest Diagnostics by 1.2% in the second quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock worth $1,099,000 after acquiring an additional 62 shares in the last quarter. PFG Private Wealth Management LLC boosted its stake in Quest Diagnostics by 5.1% in the 2nd quarter. PFG Private Wealth Management LLC now owns 1,453 shares of the medical research company’s stock worth $308,000 after purchasing an additional 71 shares during the period. Hantz Financial Services Inc. boosted its stake in Quest Diagnostics by 9.6% in the 4th quarter. Hantz Financial Services Inc. now owns 835 shares of the medical research company’s stock worth $145,000 after purchasing an additional 73 shares during the period. Koshinski Asset Management Inc. grew its position in Quest Diagnostics by 4.2% during the 1st quarter. Koshinski Asset Management Inc. now owns 2,062 shares of the medical research company’s stock worth $404,000 after purchasing an additional 84 shares in the last quarter. Finally, Wedmont Private Capital grew its position in Quest Diagnostics by 2.8% during the 2nd quarter. Wedmont Private Capital now owns 3,120 shares of the medical research company’s stock worth $647,000 after purchasing an additional 86 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Higher Truist price target: Truist raised its target for Quest Diagnostics from $250 to $260, implying additional upside, although it maintained a “hold” rating. Quest Diagnostics Given New $260 Price Target at Truist Financial
• Positive Sentiment: Growth initiatives remain supportive: Recent customer wins, advanced diagnostic offerings and artificial-intelligence initiatives are cited as potential drivers of longer-term growth. Quest has also outperformed the Nasdaq over the past year, with analysts remaining moderately optimistic. Is This the Right Time to Add DGX Stock to Your Portfolio?
• Positive Sentiment: Expanded testing opportunity: A Quest study found that nearly one-third of patients with evidence of Lyme disease exposure also had antibodies linked to another tick-borne pathogen, highlighting potential demand for broader testing. Quest Diagnostics Tick-Borne Disease Study
• Neutral Sentiment: Quest will release third-quarter 2026 results before the market opens on October 22. Investors may remain cautious ahead of the report, which will provide an update on revenue, margins and full-year guidance. Quest Diagnostics Third-Quarter Results Announcement
• Negative Sentiment: Reimbursement risk is the primary pressure: Reports indicate the government believes it has been overpaying Quest and may reduce payments next year. Investors are treating the possibility of lower reimbursement as a threat to revenue and profitability. Why Quest Diagnostics Holdings Stock Dropped Today

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers.

Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments.